Parkinson’s Disease Science

HT-6283: Investigating Neuroinflammation in Parkinson’s Disease Targeting Inflammation in Neurodegenerative Diseases

HT-6283: Investigating Neuroinflammation in Parkinson’s Disease

Targeting Inflammation in Neurodegenerative Diseases

Parkinson’s disease (PD) is a neurodegenerative disorder associated with motor dysfunction and inflammation. 20 HT-6283, an investigational NLRP3 inhibitor, is being studied for its potential to modulate neuroinflammation in PD. 21 Preclinical research suggests inhibiting NLRP3 may reduce neuroinflammatory cytokine production and potentially slow disease progression. However, further research is required to confirm these findings. 22,23Investigational Status: HT-6283 is an investigational drug and is not currently approved for the treatment of Parkinson’s disease. Further studies are needed to determine its potential activity in this disorder.

Obesity

Almost half of US adults are obese or severely obese. Lack of physical activity, unhealthy eating behavior, and, in some cases, genetics contribute to obesity. Halia is developing investigational treatments to combat obesity.

Learn More

Pain and Rheumatoid Arthritis

Rheumatoid Arthritis (RA) is an autoimmune condition where the immune system—normally the body's defender against infection and disease—attacks its own tissues. This results in pain, swelling, stiffness, and loss of joint function. Halia is developing an investigational treatment for both RA and post-surgical pain.

Learn More

Alzheimer's Disease

Alzheimer’s disease involves parts of the brain that control memory, language, problem-solving, and other thinking abilities. It can seriously affect a person’s ability to carry out daily activities. Halia is developing a potentially relevant pathway and investigational treatment for Alzheimer’s.

Learn More

Parkinson's Disease

Parkinson’s disease is a progressive disorder that affects the nervous system and the parts of the body controlled by the nerves. Tremors, stiffness, or slowing of movement are typical symptoms. Halia is developing a potential brain-penetrant compound to treat the disease.

Learn More

Cancer

Cancer occurs when normal cells become cancerous cells that multiply and spread. Cancer is the second most common cause of death in the U.S. However, fewer people die of cancer now than 20 years ago19. Halia is developing potential pathways to prevent the onset of cancer.
Learn More